Compare JWEL & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JWEL | PMCB |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 6.3M |
| IPO Year | 2020 | 2001 |
| Metric | JWEL | PMCB |
|---|---|---|
| Price | $2.24 | $0.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 71.7K | ★ 87.9K |
| Earning Date | 05-12-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.47 | $0.47 |
| 52 Week High | $5.17 | $1.51 |
| Indicator | JWEL | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 24.65 |
| Support Level | $2.11 | N/A |
| Resistance Level | $2.54 | $0.57 |
| Average True Range (ATR) | 0.28 | 0.03 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 16.94 | 9.16 |
Jowell Global Ltd is a cosmetics, health, nutritional supplements, and household products e-commerce platform in China. The company offers its branded products to customers and also sells and distributes products from other companies on its platform. In addition, it allows third parties to open their stores on its platform for a service fee based on their sales revenues generated from their online stores and provides them with information about market needs, enabling them to manage their sales effort, as well as an effective platform to promote their brands. The company currently operates under four sales channels: Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing.
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.